Results Published from Trial of Siponimod in Secondary Progressive MS

The Lancet recently published an article demonstrating the efficacy of a new MS medication, Siponimod, in secondary progressive MS patients. Siponimod is very similar to a currently available medication, called fingolimod or gilenya, but may have a better safety profile. The results of the study were modest and research on this drug is ongoing. 

To read more about the published article please click here